Clinical Trial: NCT06120075
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Arcus Biosciences, Inc. |
| Information Provided By: | Arcus Biosciences, Inc. |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Official Title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Conditions
Advanced Cancer
Intervention / Treatment
- Drug: AB801
- Drug: Docetaxel
Other Study ID Numbers
- ARC-27
Start Date (Actual)
2024-01-19
Primary Completion Date (Actual)
2026-04-29
Study Completion Date (Actual)
2026-04-29
Enrollment (Actual)
29
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Arcus Biosciences, Inc. |
| Information Provided By: | Arcus Biosciences, Inc. |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Official Title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Conditions
Advanced Cancer
Intervention / Treatment
- Drug: AB801
- Drug: Docetaxel
Other Study ID Numbers
- ARC-27
Start Date (Actual)
2024-01-19
Primary Completion Date (Actual)
2026-04-29
Study Completion Date (Actual)
2026-04-29
Enrollment (Actual)
29
Study Type
Interventional
Phase
Phase 1